HR Execs on the Move

PayLess Drug Stores

www.paylessdrug.com

 
PayLess Drug Stores is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Portland, OR. To find more information about PayLess Drug Stores, please visit www.paylessdrug.com
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Storandt Pann Margolis

Storandt Pann Margolis is a La Grange, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Vitruvias Therapeutics

Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.

Health Bridge Fitness

Health Bridge Fitness is a Crystal Lake, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diller Medical Inc

Diller Medical Inc is a Bluffton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.